相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A new blood test analyzes circulating tumor DNA to personalize cancer treatment by identifying specific mutations and recommending tailored therapies. - The Target National trial at The Christie hospital aims to recruit 6,000 patients to assess if 'liquid biopsies' improve outcomes, potentially becoming routine on the NHS. - Oxford University researchers developed the TriOx test, demonstrating high sensitivity (94.9%) and specificity (88.8%) in detecting early-stage cancers across six types. - Early results from personalized treatment approaches show significant benefits, such as tumor shrinkage in advanced cases, highlighting the potential for improved patient outcomes.
- Noddy Holder, the frontman of Slade, was diagnosed with oesophageal cancer five years ago and initially given only six months to live. - Holder underwent an experimental chemotherapy trial at The Christie Hospital in Manchester, which has significantly extended his life. - Despite the initial prognosis, Holder has responded well to the treatment and is reportedly feeling good, though doctors avoid using the term 'cure'. - The singer's wife, Suzan Holder, revealed the diagnosis and treatment in an emotional piece, highlighting the family's resilience and support system.
- The Christie NHS Foundation Trust partners with Innovative Trials to enhance cancer clinical trial recruitment, focusing on improving access for patients in six key UK regions. - The initiative specifically targets underrepresented black, Asian, and minority ethnic communities, aiming to increase trial participation through culturally appropriate outreach materials. - A network of cancer centers will be established across the UK to enable local trial participation, addressing the fact that fewer than 50% of cancer patients recall discussing clinical trials post-diagnosis.
